GE HealthCare: 3 Key Takeaways for Long-Term Investors
On its third-quarter 2026 earnings call, held on Oct. 28, 2026, GE HealthCare (NASDAQ:GEHC) raised its full-year guidance after delivering 6.2% organic revenue growth and expanding operating margins. Expanding demand for advanced imaging equipment and diagnostic drugs added $2.5 billion to its backlog over the past year. Three key takeaways from management's comments stand out for long-term investors. The Pharmaceutical Diagnostics division, or PDX, sells contrast agents used during scans, generating cash tied directly to overall procedure volume rather than volatile equipment budgets. Management uses an internal operating process called Heartbeat to streamline factory floors and resolve supply bottlenecks across manufacturing sites. Continue reading